Corteria

Corteria Pharmaceuticals

This biopharmaceutical company develops first-in-class drugs for patients with heart failure subpopulations, obesity and autosomal dominant polycystic kidney disease.

Corxel

This biopharmaceutical company develops therapies for patients with cardiometabolic diseases, including obesity, type 2 diabetes, and acute ischaemic stroke.

Cardurion Pharmaceuticals

This clinical-stage biotechnology company develops therapeutic drugs for patients with heart failure and other cardiovascular diseases.

Imbria

This clinical-stage biotechnology company develops novel therapies targeting cardiac energy metabolism for patients with serious cardiovascular and metabolic diseases.

Corvidia Therapeutics

This clinical-stage biotechnology company develops precision therapies for patients with chronic kidney disease who are at high risk of cardiovascular events.

Marea Therapeutics

This biotechnology company develops medicines for cardiometabolic and cardioendocrine diseases using human genetic data for patients with unmet medical needs.

AnaCardio

This biopharmaceutical company develops oral small-molecule drugs to improve cardiac contractility in patients with heart failure.

Kailera

This biopharmaceutical company develops injectable and oral therapies for the treatment of obesity and related metabolic conditions.